Vascular Inflammation in Psoriasis - Apremilast
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cardiovascular Diseases
- Psoriasis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Masking Description: Imaging data files will be sent to the central core of the National Institutes of Health (NIH) Imaging Lab for measuring the standardized uptake values (SUVs). The NIH central PET/CT readers will be blinded to time point of scan via Digital Imaging and Communication in Medicine (DICOM) file editing applied by the University of Pennsylvania.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The primary objectives of this study are to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis. FDG-PET/CT will be used to assess vascular inflammation, with multi-volumetric product, tissue-t...
The primary objectives of this study are to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis. FDG-PET/CT will be used to assess vascular inflammation, with multi-volumetric product, tissue-to-background ratio and total atherosclerotic burden, and body composition via volumetric quantification. This is a year-long, single arm, open label study.
Tracking Information
- NCT #
- NCT03082729
- Collaborators
- Celgene Corporation
- National Heart, Lung, and Blood Institute (NHLBI)
- Investigators
- Not Provided
Get Well Soon